

12 December 2024

**Physiomics plc**  
**("Physiomics" or the "Company")**

**Contract Award**

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.

The project will involve the application of Pharmacokinetic-Pharmacodynamic (PK/PD) modelling to inform the Target Candidate Profile ("TCP") of a key asset in Numab Therapeutics' pipeline. Delivery of the project is expected to complete within the next 6 months.

This latest collaboration builds on Physiomics' strong relationship with Numab Therapeutics AG and highlights its expertise in using modelling and simulation approaches to accelerate the development of innovative therapies across a range of therapeutic areas and across the entire drug development pathway, including early discovery and development.

Dr Peter Sargent, CEO of Physiomics, commented:

*"We are excited to build on our partnership with Numab Therapeutics AG and contribute to the advancement of this innovative therapy. This collaboration highlights our growing ability to provide comprehensive support to our clients, addressing critical challenges and adding value at multiple stages of the drug development process."*

For more information about Physiomics and its services, please visit [www.physiomics.co.uk](http://www.physiomics.co.uk).

**Enquiries:**

**Physiomics plc**  
Dr Peter Sargent, CEO  
+44 (0)1235 841575

**Hybridan LLP (Broker)**  
Claire Louise Noyce  
+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**  
James Dance & James Bellman  
+44 (0)20 7409 3494

**Notes to Editor**

**About Physiomics**

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled.

Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTGPGWPPUPCGUP